CRTS

CellResearch Therapeutics (CRT) is a clinical-stage biotechnology company and a spin-out of CellResearch Corporation, a global leader in umbilical cord lining stem cell technology. The company leverages its proprietary platform to develop regenerative therapies using mesenchymal and epithelial stem cells harvested from the umbilical cord lining. Its lead program is focused on the treatment of diabetic foot ulcers, which has advanced into Phase 2 clinical trials. Beyond wound care, CRT is exploring applications in dermatology, including androgenetic alopecia, and other chronic conditions such as COPD and erectile dysfunction. The company's technology is supported by a robust patent portfolio covering the isolation and therapeutic use of these unique stem cell populations.